Answers are grounded in this paper and cite their sources.
Integrative multi-omic analysis reveals a hypoxia-driven relapse state in resected non-small cell lung cancer, indicating STEAP2 inhibition may reduce post-surgical metastatic recurrence.
Metastatic relapse after curative-intent resection suggests that dissemination-associated programs may precede clinically detectable spread. We integrated clinical stratification with whole-exome sequencing, bulk transcriptomics, proteomics, single-cell transcriptomics and digital pathomics in a lung adenocarcinoma-predominant non-small cell lung cancer cohort. Relapse-prone primary tumors showed chromosomal instability, APOBEC-associated mutational features, immune attenuation and recurrent HIF/hypoxia-associated transcriptional programs, supported by higher CA9 and HIF-1α staining in the pooled progression/metastasis group. Single-cell trajectories showed progressive acquisition of related malignant states. Integrative prioritization identified STEAP2 as a candidate effector associated with HIF-1α stability and selected invasive phenotypes. Structure-guided screening nominated ZD93 as a candidate STEAP2-directed compound. ZD93 attenuated hypoxia-associated outputs and migration in vitro and was associated with fewer histologically confirmed lesions and longer humane-endpoint survival in exploratory xenograft analyses. Together, these findings delineate a HIF-associated progression-prone state that precedes relapse and nominate STEAP2 as a candidate vulnerability requiring mechanistic and therapeutic validation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: